Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
25 juin 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Zevra Therapeutics Expands Executive Leadership Team
25 juin 2024 07h30 HE
|
Zevra Therapeutics
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra...
FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic Rare Disease in Nephrology
17 juin 2024 08h30 HE
|
NovelMed Therapeutics Inc
-- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients A Phase II, Efficacy Trial in adult AAV patients has...
American Kidney Fund Convenes Rare Kidney Disease Action Network to Advocate for Policies and Regulations that Help Patients with Rare Causes of Kidney Disease
13 juin 2024 13h07 HE
|
American Kidney Fund
ROCKVILLE, Md., June 13, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce the launch of the Rare Kidney Disease Action Network (RKDAN), a new effort that will play a...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
11 juin 2024 06h00 HE
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
11 juin 2024 01h00 HE
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
30 mai 2024 13h41 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow
30 mai 2024 08h00 HE
|
Bionano Genomics
Bionano announces a record 39 scientific presentations and posters highlighting optical genome mapping at two upcoming global cytogenetics conferences.
Global Rare Disease Diagnostics Market is Projected to Hit USD 88,969.27 Million by 2032, With a CAGR of 9.2% From 2024 to 2032- Report by Polaris Market Research (PMR)
23 mai 2024 09h30 HE
|
Polaris Market Research & Consulting LLP
New York, May 23, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global Rare Disease Diagnostics Market size is projected to grow from USD 40,227.42 million in 2023 to USD 88,969.27 million by 2032,...
Fc and Glycoengineered Antibodies Research 2024: Market Experiences Over 30% Growth in Collaborations in Past Two Years, Fueled by Strategic Partnerships - Long-term Forecasts to 2035
22 mai 2024 04h47 HE
|
Research and Markets
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Fc and Glycoengineered Antibodies Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Engineering, Type of Therapy,...